Phylogica specialises in the development of cell penetrating peptides, with a focus on developing novel therapies to treat eye diseases.

Phylogica to raise $27m

Biotech company Phylogica has announced plans to raise $26.8 million through a rights issue, fully underwritten by chairman and major shareholder Alan Tribe, with the proceeds used primarily to fund preclinicial studies for its leading drug molecule.


(existing subscribers)

The password field is case sensitive.
Request new password

Share Price

Closing price for the last 90 trading days
Powered by Morningstar ®

Top 10 Shareholders

Substantial shareholders as published in the annual report.
Powered by Morningstar ®